Hyloris Pharmaceuticals SA (EBR:HYL)

Hyloris Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 27, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	192	183	357	311	447	245
Market Cap Growth	29.43%	-48.71%	14.84%	-30.44%	82.10%	-
Enterprise Value	175	157	319	260	402	187
Last Close Price	6.86	6.54	12.75	11.60	17.30	9.50
PS Ratio	22.71	18.76	94.97	130.24	144.35	1402.34
PB Ratio	6.65	5.70	9.14	5.77	9.30	4.16
P/TBV Ratio	7.71	6.03	10.13	5.97	9.67	4.26
EV/Sales Ratio	20.64	16.09	84.88	108.83	129.77	1068.71
Debt / Equity Ratio	0.06	0.06	0.05	0.02	0.18	0.14
Net Debt / Equity Ratio	-0.60	-0.69	-0.75	-0.80	-0.87	-0.95
Net Debt / EBITDA Ratio	3.01	3.59	1.86	3.77	4.06	11.13
Net Debt / FCF Ratio	2.53	3.22	2.22	3.28	3.68	12.25
Asset Turnover	0.21	0.22	0.07	0.04	0.05	0.01
Quick Ratio	3.76	4.12	5.14	8.32	3.53	30.33
Current Ratio	3.82	4.15	5.22	8.63	3.60	31.24
Return on Equity (ROE)	-20.18%	-17.81%	-33.08%	-23.35%	-21.62%	-29.24%
Return on Assets (ROA)	-9.03%	-8.94%	-18.27%	-11.58%	-9.73%	-8.44%
Return on Capital Employed (ROCE)	-19.40%	-18.60%	-38.70%	-20.90%	-21.30%	-7.60%
Earnings Yield	-3.34%	-3.46%	-4.31%	-3.83%	-2.59%	-2.91%
FCF Yield	-3.59%	-3.79%	-3.67%	-4.22%	-2.54%	-1.86%
Buyback Yield / Dilution	4.61%	-	-2.95%	-5.29%	-18.40%	-51.63%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.